Company: ZVRA
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001437749-25-016523
Chunk: 70

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 70
---
, and narcolepsy. KP1077 has a sole active pharmaceutical ingredient of serdexmethylphenidate (“SDX”), the Company's proprietary prodrug of d-methylphenidate (“d-MPH”). The FDA has granted KP1077 orphan drug designation for the treatment of IH.
    
   Basis of Presentation
    
   The Company prepared the unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the Company’s opinion, reflect all adjustments, including normal recurring items that are necessary. All significant intercompany accounts and transactions have been eliminated in consolidation.

     Registration Statements on Form S-3

       On 
       February 5, 2024, Zevra filed a registration statement on Form S-
      3 (File 
      No. 
      333-
      276856) registering an aggregate of 
      2,269,721 shares of Zevra’s common stock. On 
       April 5, 2024, the Company filed an amendment to such registration statement, which was declared effective on 
       April 8, 2024.

       On 
       June 4, 2024, the Company filed a registration statement on Form S-
      3 (File 
      No. 
      333-
      279941) (the 
       “June 2024 Registration Statement”) under which the Company 
       may sell securities, including as 
       may be issuable upon conversion, redemption, repurchase, exchange or exercise of securities, in 
      one or more offerings up to a total aggregate offering price of
      $350.0 million,
      $75.0 million of which was allocated to the sale of the shares of common stock issuable under the 
      2024 ATM Agreement (as described further below). The registration statement was declared effective on 
       June 13, 2024.

       August 2024 Offering

       On 
       August 8, 2024, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and William Blair & Company, L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”), in connection with the offering,